NRM gets a haircut today.CNBC report was not very glowing on alzemed. Analyst said Neurochem is very speculative at these levels. Notice how the stock tanked after the report. If the phase III trials aren't spectacular you folks better start praying or learn how to swim cause NRM will sink faster than the Titanic. This POS is waaaaaaaaaaaay overpriced.
Harv